loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Avapritinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Avapritinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 439,452Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Blueprint Medicines to Present at Upcoming Investor Conferences
    Blueprint Medicines to Present at Upcoming Investor Conferences

    10 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-302232128.html

    PR NEWSWIRE
    10 Sep 2024
    Share Share
    Blueprint AYVAKIT Data At EAACI EHA Highlight Sustained Benefit
    Blueprint AYVAKIT Data At EAACI EHA Highlight Sustained Benefit

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-at-eaaci-and-eha-annual-meetings-highlighting-sustained-clinical-benefits-of-ayvakitayvakyt-avapritinib-302160044.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance
    Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance

    02 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-reports-strong-first-quarter-2024-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302133890.html

    PR NEWSWIRE
    02 May 2024
    Share Share
    Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data
    Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data

    23 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-highlights-ayvakit-avapritinib-long-term-efficacy-and-safety-data-and-advances-in-mast-cell-disease-research-at-2024-aaaai-annual-meeting-302069445.html

    PR NEWSWIRE
    23 Feb 2024
    Share Share
    Blueprint boosts Ayvakit peak sales estimate to $2B
    Blueprint boosts Ayvakit peak sales estimate to $2B

    15 Feb 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/blueprint-boosts-ayvakit-peak-sales-estimate-2b-key-rare-disease-expansion-accelerates

    FIERCE PHARMA
    15 Feb 2024
    Share Share
    EC approves treatment for rare haematological disorder
    EC approves treatment for rare haematological disorder

    13 Dec 2023

    // EUROPEAN PHARMACEUTICAL REVIEW

    https://www.europeanpharmaceuticalreview.com/news/190025/ec-approves-treatment-for-ism/

    EUROPEAN PHARMACEUTICAL REVIEW
    13 Dec 2023
    Share Share